Stockscreener 앱 받기
0.4257
0.95%
-0.0041
시장 영업 전:
.42
-0.0057
-1.34%
전일 마감가:
$0.4298
열려 있는:
$0.42
하루 거래량:
1.32M
Relative Volume:
0.22
시가총액:
$21.07M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.0278
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+8.07%
1개월 성능:
-25.00%
6개월 성능:
-59.84%
1년 성능:
-84.17%
1일 변동 폭
$0.4195
$0.4341
1주일 범위
$0.387
$0.4389
52주 변동 폭
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.4257 | 15.79M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Certain Options of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Can Moleculin Biotech Inc. grow without dilutionJuly 2025 Recap & Advanced Swing Trade Entry Alerts - خودرو بانک
Moleculin Biotech (MBRX) Files to Sell 64.86 Million Common Shar - GuruFocus
Moleculin Biotech files prospectus for resale of common stockSEC Filing - MarketScreener
FOMO Trade: Will Moleculin Biotech Inc benefit from geopolitical trendsJuly 2025 Opening Moves & Technical Analysis for Trade Confirmation - خودرو بانک
Death Cross: Why is Moleculin Biotech Inc stock going up2025 Earnings Impact & Free Community Consensus Stock Picks - خودرو بانک
Aug PostEarnings: Can Moleculin Biotech Inc. stock outperform in a bear market2025 Retail Activity & Step-by-Step Trade Execution Guides - خودرو بانک
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Risk Off: Why is Moleculin Biotech Inc stock going up2025 Price Targets & Growth Focused Investment Plans - خودرو بانک
Published on: 2025-09-17 13:31:31 - خودرو بانک
Day Trade: Is CDRPRC a potential multi baggerTrade Exit Report & Fast Moving Market Watchlists - خودرو بانک
Aug Setups: Is Moleculin Biotech Inc likely to announce a buyback2025 Bull vs Bear & Daily Stock Momentum Reports - خودرو بانک
Treasury Yields: What are Moleculin Biotech Incs earnings expectations2025 Market Trends & High Win Rate Trade Alerts - خودرو بانک
Volume Report: Is Moleculin Biotech Inc forming higher highs and higher lowsJuly 2025 Price Swings & Daily Price Action Insights - خودرو بانک
Surprises Report: Can Moleculin Biotech Inc deliver consistent dividends2025 Big Picture & Trade Opportunity Analysis - خودرو بانک
Is Moleculin Biotech Inc. stock undervalued right nowJobs Report & Weekly High Return Opportunities - خودرو بانک
H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Moleculin Biotech stock - Investing.com
Moleculin Biotech accelerates recruitment in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - GlobeNewswire
Moleculin Biotech Expands Global Phase 2B/3 Trial - TipRanks
Moleculin Biotech Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - MarketScreener
Moleculin expands AML trial sites globally, targets 45 patients by Q4 - Investing.com
Moleculin Biotech, Inc. Expands Global Recruitment for MIRACLE Trial in Europe and the US, Aiming for 45 Patients by Q4 2025 - Quiver Quantitative
Global Expansion: Moleculin's MIRACLE Leukemia Trial Reaches 13 Patients, Targeting 45 for Key Data Analysis - Stock Titan
Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment - TipRanks
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - GlobeNewswire
Moleculin Biotech Releases New Corporate Presentation - TipRanks
Moleculin enrolls first EU patients in pivotal AML cancer trial By Investing.com - Investing.com South Africa
Will Moleculin Biotech Inc. Sustain Its Chart BreakoutJuly 2025 Drop Watch & Smart Investment Allocation Tips - beatles.ru
Moleculin enrolls first EU patients in pivotal AML cancer trial - Investing.com
Moleculin doses first EU patient in phase 3 pivotal MIRACLE trial for treatment of Acute Myeloid Leukemia - MarketScreener
First EU Patients Enrolled: Moleculin's Phase 3 MIRACLE Trial Targets Hard-to-Treat Leukemia - Stock Titan
Moleculin Biotech Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Accurate Intraday Trade Tips - beatles.ru
Is Moleculin Biotech Inc. stock a smart retirement pickQuarterly Risk Review & Capital Efficient Trading Techniques - 뉴스영
Moleculin Biotech Completes Promising Annamycin Trial - MSN
Is Moleculin Biotech Inc. in a consolidation phaseShare Buyback & Daily Entry Point Alerts - خودرو بانک
Is Moleculin Biotech Inc. stock a buy or sellPortfolio Value Report & AI Powered Market Entry Strategies - خودرو بانک
What’s the outlook for Moleculin Biotech Inc.’s sectorJuly 2025 Trends & Weekly Top Performers Watchlists - خودرو بانک
Does Moleculin Biotech Inc. align with a passive investing strategyCEO Change & Smart Allocation Stock Tips - خودرو بانک
Backtesting results for Moleculin Biotech Inc. trading strategies2025 Investor Takeaways & Expert Verified Movement Alerts - Newser
Can Moleculin Biotech Inc. expand into new marketsEarnings Beat & Free Daily Entry Point Trade Alerts - خودرو بانک
Moleculin Biotech Inc. stock trend forecastQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - Newser
Custom watchlist performance reports with Moleculin Biotech Inc.Market Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Long term hold vs stop loss in Moleculin Biotech Inc.Weekly Trend Summary & Low Risk High Win Rate Stock Picks - Newser
Volume spikes in Moleculin Biotech Inc. stock – what they meanJuly 2025 Trends & AI Powered Trade Plan Recommendations - Newser
Why Moleculin Biotech Inc. is moving todayPortfolio Value Report & Low Drawdown Trading Strategies - Newser
Using Bollinger Bands to evaluate Moleculin Biotech Inc.July 2025 Institutional & Real-Time Chart Pattern Alerts - Newser
Will Moleculin Biotech Inc. stock hit new highs in YEARJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - خودرو بانک
Is Moleculin Biotech Inc. showing signs of accumulationTrend Reversal & Verified Trade Idea Suggestions - Newser
Why is Moleculin Biotech Inc. stock going upPortfolio Value Summary & AI Driven Price Forecasts - خودرو بانک
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
2.51%
자본화:
|
볼륨(24시간):